Permanent product Record

GHOST

GHOST LEGEND ALL OUT

UNREADABLERecord last observed August 18, 2026very-high-stim

GHOST LEGEND ALL OUT has a unreadable Record. Last observed August 18, 2026. The current public formula contains 11 declared ingredient lines. Comparable formula history is not yet available.

Current Record

The current declared formula.

Printed label wording stays separate from FormulaSignal's normalized identity. Current formula observed August 18, 2026.

Serving size
Not recorded
Servings
Not recorded
Caffeine
400 mg per serving
Formula scope
FLAVOR SPECIFIC
GHOST LEGEND ALL OUT, current declared formula observed August 18, 2026. Each row gives the printed label wording, the declared amount, and FormulaSignal's normalized identity.
Original label wordingDeclared amountNormalized identity
Vitamin C (as Ascorbic Acid) (PureWay-C)250 mgvitamin c as ascorbic acid pureway-c
Full Yield Citrulline6000 mgfull yield citrulline
Full Yield Beta-Alanine3200 mgfull yield beta-alanine
Full Yield Betaine2500 mgfull yield betaine
L-Tyrosine (Vegan Fermented)2000 mgl-tyrosine
Alpha-GPC (Alpha-Glyceryl Phosphoryl Choline 50%) (delivering 300mg Alpha-GPC)600 mgalpha-gpc 50% material
Caffeine400 mgcaffeine
PureWay-C (Ascorbic Acid and Citrus Bioflavonoids)390 mgpureway-c ascorbic acid and citrus bioflavonoids
Theobromine100 mgtheobromine
Bitter Orange (Citrus aurantium) Fruit extract60 mgbitter orange citrus aurantium fruit extract
AstraGin (Astragalus membranaceus Root extract, Panax notoginseng Root extract)50 mgastragin astragalus membranaceus root extract panax notoginseng root extract

Serving economics

Facts and calculations stay labeled.

Captured commercial fact
Observed price, basis not established: $54.99
Price observation
August 3, 2026
Captured commercial serving count
20 servings per container
Deterministic calculation
$54.99 ÷ 20 = $2.75 per serving

Historical timeline

Comparable formula states.

Dates below are observation dates. They are not exact reformulation dates.

Historical formula evidence is not yet sufficient for a reliable comparison. This does not establish that the product never changed.

Confirmed Signals

Reviewed changes in the public Record.

No confirmed public Signal is associated with this product. This is not a claim that the product never changed.

Research-dose context

Selected evidence, not a universal effective dose.

These comparisons retain the studied protocol, source, and limitations. They do not establish safety, effectiveness, or a dose recommendation for this product.

A2

L-tyrosine

Product declaration
L-Tyrosine (Vegan Fermented): 2000 mg
Selected studied range
2000 to 2000 mg
Protocol and duration
per day for five days, in the cadet study
Studied context
Studied as the dietary precursor to norepinephrine for mitigating cognitive performance decrements under acute stress. A 2015 Military Medicine evidence review (rapid evidence assessment, 14 trials: 10 RCTs + 4 controlled clinical trials) issued a "weak recommendation" in favor of tyrosine for cognitive stress specifically, stating "all studies showed a positive effect" on that outcome. A widely cited primary study (Deijen et al. 1999, Brain Research Bulletin) gave cadets 2 g tyrosine daily for five days during a combat training course and found better memory and tracking-task performance, plus lower systolic blood pressure, versus a carbohydrate control.
Limitations
The 2015 Military Medicine review states explicitly that "no recommendation could be made" for tyrosine's effect on physical performance under stressful physical conditions, and concludes "available evidence is insufficient to make confident recommendations on the effectiveness of tyrosine for mitigating stress effects on physical/cognitive performance" overall, despite the positive signal on cognition. A separate heat-stress study found tyrosine ingestion did not influence cognitive function or physical performance during exercise heat stress despite raised serum tyrosine. NIH ODS's exercise/athletic-performance fact sheet does not cover tyrosine at all.

Selected evidence: Deijen et al., Brain Research Bulletin, 1999

A1

Theobromine

Product declaration
Theobromine: 100 mg
Selected studied range
No dose range selected
Protocol and duration
Not recorded in the selected comparison
Studied context
EFSA's Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF), in its 2017 opinion on xanthine alkaloids from the flavoring priority list, treats theobromine as a major metabolite of caffeine. Roughly 11% of an ingested caffeine dose converts systemically to theobromine. And states that because "only limited toxicity data in humans are available" for theobromine directly, its safety assessment leans on the extensive caffeine safety literature (EFSA's 2015 caffeine opinion) rather than an independent human-efficacy dataset for theobromine as a standalone ergogenic ingredient.
Limitations
No sports-performance-specific position stand or ISSN evaluation of theobromine as a standalone ergogenic ingredient was located in this research pass. EFSA's own framing acknowledges limited independent human toxicity data on theobromine itself.

Selected evidence: EFSA Flavouring Group Evaluation 49 Revision 1, 2017 · Open source

A2

Caffeine

Product declaration
Total caffeine from all declared sources: 400 mg
Selected studied range
140 to 420 mg
Protocol and duration
2 to 6 mg per kg body mass, 15 to 60 minutes before exercise, shown here for a 70 kg adult
Studied context
Studied for endurance-type aerobic exercise (moderate to large ergogenic effect, most consistent evidence category per ISSN 2021), muscular endurance and movement velocity in resistance exercise (small to moderate effects), sprinting/jumping/throwing (2-7% improvements), and cognitive attention/vigilance under fatigue. NIH ODS notes it "might enhance performance in endurance-type activities... And intermittent, long-duration activities."
Limitations
Minimal effective dose remains unclear. Repeated-sprint performance benefit is inconsistent and the ISSN position stand says this "requires further research." Effects of habitual/chronic caffeine use on the ergogenic response are described as equivocal.

Selected evidence: ISSN position stand on caffeine and exercise performance, 2021, with NIH ODS · Open source

Cautions and regulatory records

A filing and a documented risk are not the same thing.

These attach to declared ingredients, not to this product as a whole. Nothing here establishes that the product is safe or unsafe. Talk with a qualified health professional.

Documented cautions on declared ingredients

  • SAFETY ADVISORY · A1

    Stimulant-load gate. The current record declares 400 mg of caffeine per serving, which triggers FormulaSignal's 300 mg stimulant-load gate. That 300 mg is our own screening threshold, not a regulatory limit. We set it there because NIH ODS summarizes an FDA reference point of 400 mg per day for healthy adults, so a single serving at 300 mg uses three quarters of that daily figure before any coffee, tea, or soda is counted. The gate flags that headroom is small. It is not a finding that the product is unsafe, and individual responses vary.

    Dietary Supplements for Exercise and Athletic Performance, NIH Office of Dietary Supplements · Open source

  • SAFETY ADVISORY · A2

    Alpha-GPC 50% material. This material is standardized to Alpha-GPC. A 2021 JAMA Network Open study of about 12 million adults reported an association between alpha-GPC use and 10-year stroke risk, in a dose and duration response pattern. The authors flag confounding, and association is not causation.

    Association of L-alpha Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years, JAMA Network Open · Open source

Where the sources disagree

What we could not read cleanly.

A disagreement between sources is recorded rather than smoothed into one confident number. None of these is a Signal.

No source conflict is recorded on this Record. That is not a claim that every source agrees, only that none we read disagreed.

Evidence

Audit the material claims.

  • GHOST

    P1 current formula source · observed August 18, 2026 · accessed August 18, 2026

    Open source evidence
  • GHOST

    P1 commercial capture · observed August 3, 2026 · accessed August 3, 2026

    Open source evidence

Go deeper

Ask now, or keep watch.

No released consumer report is available for this product. Browse Reports.